Core Insights - Clearmind Medicine Inc. has completed the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial for CMND-100, a proprietary oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Clinical Trial Details - The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - Six patients have been successfully enrolled in the trial, with two at Johns Hopkins University and four at Yale School of Medicine [2] - The trial is registered on ClinicalTrials.gov under the identifier NCT05913752 [4] Management Commentary - The CEO of Clearmind expressed enthusiasm about reaching a key milestone in the trial and highlighted the efficient enrollment process, which was completed within an excellent timeline [4]

Core Insights - Clearmind Medicine Inc. has announced the publication of a U.S. patent application for a combination therapy involving 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, targeting binge behavior disorders [1][2] - The therapy aims to address various binge behaviors, including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct, by leveraging MEAI's neuroplastic properties [2][3] - The company has filed a total of 13 patents related to its collaboration with SciSparc Ltd., focusing on conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [5] - The company's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Strategic Goals - The CEO of Clearmind emphasized the company's mission to pioneer safe and effective treatments for binge behaviors, aiming to meet unmet needs in addiction medicine [4][8] - The combination of MEAI and PEA is positioned as a potentially safer and more effective treatment option compared to existing therapies [2][4]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a U.S. patent application for a combination therapy targeting binge behavior disorders [1][2] - The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, such as Palmitoylethanolamide (PEA), which may provide a new approach to treating various behavioral addictions [2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs based on THC and non-psychoactive cannabidiol [4] - The company is currently working on treatments for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4] Collaboration Details - The collaboration with Clearmind focuses on the potential of PEA-MEAI combinations to address conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data suggests that this combination therapy may effectively mitigate binge episodes while preserving natural reward pathways [3] Clearmind Medicine Inc. Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing novel psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a diverse intellectual property portfolio consisting of 19 patent families and 31 granted patents [5]

Core Insights - Clearmind Medicine Inc. successfully held its inaugural Annual Scientific Advisory Board (SAB) meeting, gathering eight experts in relevant fields to provide strategic guidance on the company's clinical and preclinical programs [1][2]. Group 1: Clinical Development - The SAB focused on Clearmind's lead candidate, 5-Methoxy-2-aminoindane (MEAI), which is currently in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD) [2]. - MEAI was highlighted for its unique pharmacological profile and promising safety data, suggesting potential advantages over emerging GLP-1 therapies, making it a potentially safe, accessible, and cost-effective treatment option [2]. - Preclinical findings indicate MEAI's potential to address not only AUD but also obesity, metabolic syndrome, and mental health challenges faced by veterans [2]. Group 2: Strategic Opportunities - The SAB explored opportunities to strengthen Clearmind's clinical development and potential partnerships, reviewing the company's robust intellectual property portfolio, which includes 31 granted patents worldwide [3]. - Insights from the SAB will guide the company's development strategy as it aims to deliver transformative psychedelic-derived therapies for global health challenges [3]. Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address major under-treated health problems, including alcohol use disorder [4]. - The company's intellectual property portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [5].

As filed with the Securities and Exchange Commission on September 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 ...

Core Points - Clearmind Medicine Inc. has entered into securities purchase agreements with institutional investors to issue convertible promissory notes totaling up to $10 million [1][3] - The initial closing involved the issuance of notes worth $555,556 for a purchase price of $500,000 [1] - The company plans to use the proceeds from the notes for working capital, general corporate purposes, and potential acquisitions [3] Group 1 - The company will issue additional notes worth $1,944,444 for a purchase price of $1,750,000 after the effectiveness of a registration statement [3] - Clearmind may request additional purchases of notes up to $2,500,000 per quarter, totaling $7,500,000, starting three months after the second initial closing [3][4] - Each note will be issued at 90% of the principal amount, accruing interest at 4%, increasing to 14% upon default, and is to be repaid in ten equal monthly installments starting 18 months after issuance [5] Group 2 - Clearmind is focused on developing psychedelic-derived therapeutics to address under-treated health issues, including alcohol use disorder [6] - The company holds a portfolio of nineteen patent families with 31 granted patents and aims to acquire additional intellectual property [6] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [7]

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended July 31, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | July 31, | | | October 31, | | --- | --- | --- | --- | --- | | | 2025 | | | 2024 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents | $ 3,495,338 | | $ | 6,57 ...

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in the publication of an international patent application under the Patent Cooperation Treaty (PCT) [1] - The patent application covers a combination therapy of Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) aimed at treating metabolic syndrome and obesity [2] - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The collaboration has led to the filing of 13 patent families across multiple jurisdictions, focusing on innovative therapies for mental health disorders and metabolic conditions [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies, with ongoing programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [5] - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing psychedelic-derived therapeutics for health issues like alcohol use disorder, with a portfolio of 19 patent families [6]

Core Insights - Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval from Hadassah Medical Center for its Phase 1/2a clinical trial of CMND-100, aimed at treating Alcohol Use Disorder (AUD) [1][3][4] - The trial will also involve other prestigious institutions such as Yale School of Medicine and Johns Hopkins University [2] - The approval follows previous regulatory milestones, including FDA clearance of the Investigational New Drug (IND) application [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including AUD [5] - The company holds a portfolio of nineteen patent families with 31 granted patents and plans to seek additional patents as necessary [6] Clinical Trial Details - The Phase 1/2a trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption [4] - The global burden of AUD is significant, accounting for 4.7% of all deaths worldwide, highlighting the need for effective treatments [4]